NZ534304A - Formulations comprising psychotropic drugs and selenium - Google Patents

Formulations comprising psychotropic drugs and selenium

Info

Publication number
NZ534304A
NZ534304A NZ534304A NZ53430403A NZ534304A NZ 534304 A NZ534304 A NZ 534304A NZ 534304 A NZ534304 A NZ 534304A NZ 53430403 A NZ53430403 A NZ 53430403A NZ 534304 A NZ534304 A NZ 534304A
Authority
NZ
New Zealand
Prior art keywords
selenium
drug
treatment
clozapine
schizophrenia
Prior art date
Application number
NZ534304A
Inventor
Krishnarao Sitaramrao Vaddadi
Original Assignee
Laxdale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laxdale Ltd filed Critical Laxdale Ltd
Publication of NZ534304A publication Critical patent/NZ534304A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Psychiatry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is the use of clozapine together with any biologically assimilable form of selenium in the manufacture of a medicament for the treatment or prevention of schizophrenia. The use of these compounds as a treatment for schizophrenia results in reduced incidence of cardiovascular disease in patients.

Description

<div class="application article clearfix" id="description"> <p class="printTableText" lang="en">New Zealand Paient Spedficaiion for Paient Number 534304 <br><br> 534 <br><br> WO 03/066071 PCT/GB03/00490 <br><br> 1 <br><br> FORMULATIONS COMPRISING PSYCHOTROPIC DRUGS AND SELENIUM <br><br> Risk of cardiovascular illness is very common in patients who are also being treated for psychiatric and 5 neurological disorders. It is uncertain whether this is due to the underlying illness or whether it is due to the drugs which are used to treat that illness but many commentators have pointed out that the drugs themselves may precipitate cardiac arrhythmias, 10 myocarditis and cardiomyopathies. The information for doctors about drugs, particularly but not only ones for psychiatric and neurological disorders, authorised by regulatory authorities such as the United States Pood and Drug Administration (FDA) frequently contain 15 warnings about possible cardiovascular side effects. Clozapine is one drug which carries a high risk (GJ Killian et al, Lancet 1999; 354: 1841-5. L La <br><br> Grenade et al, N Engl J Med 2001; 345: 224-5) . Clozapine can also cause depression of white cell 20 counts and in the worst cases complete loss of normal white blood cell production (agranulocytosis). <br><br> The present invention relates to the co-administration of selenium together with a drug for the treatment or 25 prevention of psychiatric or neurological disorders and particularly with clozapine. The invention provides pharmaceutical formulations comprising a drug for the treatment or prevention of psychiatric or neurological disorders together with any biologically assimilable 30 form of selenium, such that when the drug is administered the daily dose of selenium is between 10 /xg and 2000 fig per day. <br><br> Preferably, the daily dose of selenium provided by the 35 formulations of the present invention is between 50 /xg <br><br> WO 03/066071 <br><br> 2 <br><br> PCT/GB03/00490 <br><br> and 500 /zg/day and very preferably between 150 and 300 jig/day. <br><br> The selenium may be provided in the form of selenium 5 yeast, selenomethionine, selenocysteine or any appropriate selenite or selenate compound. This may form a component of the formulation. Alternatively the selenium may be chemically linked to the drug to form a selenium-drug derivative. <br><br> 10 <br><br> The drug of the formulations of the present invention is one used for the prevention or treatment of psychiatric or neurological disorders. The drug may be one approved by a regulatory authority for such a 15 treatment, including the US Food and Drug <br><br> Administration (FDA) or the European Medicines Evaluation Agency (EMEA). The preferred invention is not to combine selenium with other multi-vitamin preparations, which have not been approved for 20 administration to patients with psychiatric or neurological disorders. Preferably, the drug is one used for the treatment or prevention of psychiatric disorders including schizophrenia and bipolar disorder. The drug clozapine is particularly suited for the 25 formulations of the present invention. <br><br> The formulations are preferably orally administrable. <br><br> In a second aspect of the invention, the selenium and 30 the drug may be formulated separately but provided in the same pack with instructions for co-administration. The present invention provides a pack containing the selenium and the drug packaged for co-administration. <br><br> WO 03/066071 PCT/GB03/00490 <br><br> 3 <br><br> In a third aspect of the invention there is provided a method for the treatment or prevention of any-neurological or psychiatric disease by the coadministration of a drug conventionally used to treat 5 that disease together with selenium in any biologically assimilable form in a daily dose of between 10 /tg and 2 000 /zg selenium per day. The treatment may be by separate administration of the drug and the selenium, or by administration of a formulation of the first 10 aspect of the invention. <br><br> The invention further provides use of a formulation of the first aspect of the invention in the manufacture of a medicament for the treatment or prevention of any 15 neurological or psychiatric disease. <br><br> The treatments are of psychiatric or neurological disorders. Preferably, the invention is used to treat psychiatric disorders including but not limited to 20 schizophrenia, bipolar disorder, depression, anxiety disorders and personality disorders. Alternatively, the invention is for the treatment or prevention of neurological disorders including but not limited to epilepsies, Parkinson's disease, dementias of both 25 Alzheimer and vascular types, Huntington's disease, <br><br> spinocerebellar ataxias, Friedreich's ataxia, myotonic, dystrophy, amyotrophic lateral sclerosis and multiple sclerosis. <br><br> 30 The present invention also provides a method for the reduction of side effects caused by administration of a drug for the treatment of a psychiatric or neurological disorder to a patient by the co-administration, separately or in a formulation according to the first 35 aspect of the invention, of the drug together with <br><br> WO 03/066071 <br><br> 4 <br><br> PCT/GB03/00490 <br><br> selenium in any biologically assimilable form to provide a daily dose of between 10 fig and 2000 fig selenium per day. <br><br> In most cases it is likely that the preferred range of selenium to used will be in the range of 50 to 500 /zg/day and very preferably in the range of 150 to 300 fig/ day. <br><br> The present invention is described in particular with reference to the treatment of cardiovascular illness in patients who are also being treated for psychiatric and neurological disorders. The cause of the risk of developing this illness is unknown and multiple factors may be involved. One pilot study has reported that schizophrenic patients on clozapine, a drug, conventionally used to treat schizophrenia, have low selenium levels (LA Linday et al, J Clin Psychopharmacol 1995; 15: 353-60). This looked at only a few patients, however, did not analyse selenium in schizophrenic patients on other drugs, and did not look at selenium levels in patients with other disorders. <br><br> For the present invention, a large study has been carried out in normal individuals, in patients with various mood disorders including depression and bipolar disorder, in schizophrenic patients on drugs other than clozapine, and in schizophrenic patients on clozapine. The results are shown in Table 1 below. Here the selenium levels are expressed in /xmol/litre and are shown as means plus or minus the Standard Error of the Mean (SEM) <br><br> 4A <br><br> followed by page 5 <br><br> It is an object of the present invention to provide a formulation of any biologically assimilable form of selenium in a daily dose of between 10 |ig and 2000 |ig together with a drug such as clozapine in the manufacture of a medicament for the treatment or prevention of neurological or psychiatric disorders or at least provide the public with a useful alternative. <br><br> WO 03/066071 <br><br> 5 <br><br> PCT/GB03/00490 <br><br> Table 1 <br><br> Healthy controls <br><br> Mood disorders <br><br> Schizophrenia clozapine <br><br> Schizophrenia other drugs <br><br> N <br><br> 56 <br><br> 36 <br><br> .57 <br><br> 42 <br><br> Mean age <br><br> 43 .1 <br><br> 40.6 <br><br> 36.1 <br><br> 37.3 <br><br> Plasma Se <br><br> 1.49 ± 0.04 <br><br> 1.39 ± 0.05 <br><br> 1.28 + 0.04 <br><br> 1.47 ± 0.06 <br><br> Red cell Se <br><br> 1.80 ± 0.08 <br><br> 1.70 ± 0.07 <br><br> 1.47 ± 0.07 <br><br> 1.70 ± 0.07 <br><br> 5 This shows that all of the groups of patients, irrespective of what drugs they were on, exhibited low selenium levels, but that the levels were exceptionally low in the schizophrenic patients on clozapine. <br><br> 10 Selenium is a constituent of many enzymes, particularly ones involved in antioxidant defences (MP Rayman, Lancet 2000; 232-240). Selenium deficiency leads to a particular risk of cardiovascular disease, especially myocarditis and cardiomyopathy. Selenium deficiency 15 also increases susceptibility to the serious cardiac complications of viral infections (MA Beck et al, Nature Medicine 1995; 1: 433-6). <br><br> The present invention is based on the inventor's 20 suggestion that selenium deficiency is a major cause of the cardiovascular and perhaps other problems which are associated with the ingestion of drugs for psychiatric and neurological disorders, and especially clozapine where selenium will also be helpful in preventing the 25 depression of white cell counts and agranulocytosis. <br><br> In order to reduce the risks of drug administration, it is now proposed that all drugs for neurological and 30 psychiatric disorders should be formulated with <br><br> WO 03/066071 PCT/GB03/00490 <br><br> 6 <br><br> sufficient selenium to prevent and correct any selenium deficiency. Though it is not clear why drugs so commonly are associated with selenium deficiency, it is now suggested that some of them increase selenium 5 excretion or impair selenium absorption into the body. It may therefore be necessary to incorporate levels of selenium into the drug formulation to provide a daily intake of selenium either around the normal daily requirement of selenium or, in appropriate cases, daily 10 intakes several times higher than that. <br><br> Various official bodies have made recommendations about the usual daily selenium requirement (M Rayman 2000, Lancet 356: 233-241). These range from a low of about 15 50 /zg/day to a high of around 100 /zg/day. However, these figures do not take into account the possibility that drugs or illnesses may interfere with selenium absorption or excretion and the present invention therefore proposes that the broad range of selenium 20 supplementation needed by those taking therapeutic drugs may range from a low of 10 /zg/day in those whose selenium intakes are adequate or near adequate to a high of 2000 /zg/day in those who have particular problems with selenium metabolism or absorption. In 25 most cases it is likely that the preferred range of supplemental selenium to be added to the drug will be in the range of 50 to 500 /zg/day and very preferably in the range of 150 to 300 /zg/day. <br><br> 30 This is illustrated by a further experimental study on giving selenium to patients with schizophrenia who were taking clozapine or other psychiatric drugs (see table 2) <br><br> 35 <br><br> WO 03/066071 <br><br> 7 <br><br> PCT/GB03/00490 <br><br> Table 2 - SELENIUM TREATMENT <br><br> ■\.Age; <br><br> .. .length. . Of illness;-.' <br><br> : ; '-■■("v" ■ ^'...Diagnosis <br><br> : i" <br><br> Date:, {■: <br><br> ^Plasma'-' <br><br> . RBC <br><br> '.."Se;/ <br><br> ■•■'STOKKtOMT '&lt;*• ..given <br><br> ^ T '. MEmrGATrpii. <br><br> Male <br><br> 25 <br><br> Since 1998 <br><br> Schizophrenia <br><br> 02/09/02 07/10/02 <br><br> 1.2 2.1 <br><br> 1.4 1.9 <br><br> 02/09/02 (200mcg) <br><br> Clozapine 450mg nocte <br><br> Female <br><br> 26 <br><br> Since 1992 <br><br> Schizophrenia <br><br> 02/09/02 07/10/02 <br><br> 1.2 <br><br> 2.3 <br><br> 1.9 <br><br> 2.4 <br><br> 12/09/02 (200mcg) <br><br> Epilim 1000/d; 4mg/d; <br><br> Zoloft 200mg/d; Marine 3g/d; Vitamin B <br><br> Female <br><br> 22 <br><br> 2 years + <br><br> Schizophrenia <br><br> 02/09/02 07/10/02 <br><br> 1.2 2.2 <br><br> 1.5 2.0 <br><br> 02/09/02 (200mcg) <br><br> Clozapine 600mg/d; <br><br> Epilim 2000mg/d; Logynon ED 1/d <br><br> Male <br><br> 41 <br><br> 25 <br><br> years <br><br> Schizophrenia Mild Autism <br><br> 02/09/02 07/10/02 <br><br> 1.1 2.3 <br><br> 1.3 2.1 <br><br> 02/09/02 (200mcg) <br><br> Clozapine 800mg/d; Losec 20mg/d; Clonazepam 3mg/d; <br><br> Benzotropine 4mg/d; + laxatives <br><br> Female <br><br> 22 <br><br> 3 years <br><br> Schizophrenia <br><br> 03/05/02 7/06/02 11/07/02 <br><br> 1.3 1.0 1.2 <br><br> 1.0 1.0 1.3 <br><br> 05/06/02 (lOOracg) <br><br> Risperidone 8mg/d; Levien ED 1/d; Quetiapine 400mg/d; Vitamin E lg/d; <br><br> FGF Iron 1/d <br><br> Male <br><br> 22 <br><br> 4 years <br><br> Schizophrenia <br><br> 02/09/02 14/10/02 <br><br> 0.8 1.9 <br><br> 1.3 1.9 <br><br> 19/09/02 (200mcg} <br><br> Clozapine <br><br> 300mg/d; <br><br> Epilim <br><br> 1500mg/d <br><br> Stelazine <br><br> 5mg/d; Maxepa <br><br> 4g/d; <br><br> Ranitidine <br><br> 300mg/d; <br><br> Benzhexol <br><br> 5mg/d; <br><br> Maxalon <br><br> 20mg/d; <br><br> Lithium <br><br> 500mg/d <br><br> Male <br><br> 28 <br><br> Since <br><br> May <br><br> 2001 <br><br> Schizophrenia <br><br> 02/09/02 07/10/02 <br><br> l.S 2.1 <br><br> 2.4 2.8 <br><br> 02/09/02 (200mcg) <br><br> Clozapine 300mg nocte <br><br> WO 03/066071 <br><br> 8 <br><br> PCT/GB03/00490 <br><br> f, <br><br> Age' <br><br> Length <br><br> ' ■ ' bf .!■'•' Illness; <br><br> ■ Diagnosis." <br><br> ii:,bate. <br><br> .-'Plasma'. <br><br> •se-' <br><br> ■■ rbc : <br><br> Se\: <br><br> !'. SEL Erj .i. U ■ <br><br> GIVEN'.;' <br><br> .^.^ICATiOW-1 <br><br> Female <br><br> 37 <br><br> 8 years <br><br> Schizophrenia <br><br> 02/09/02 07/10/02 <br><br> 1.1 2.5 <br><br> 1.5 2.4 <br><br> 02/09/02 (200mcgJ <br><br> Clozapine <br><br> 400mg/d; <br><br> Citalopram 60; <br><br> Zuclopenthixol <br><br> 300mg I.M. <br><br> 2/52; <br><br> Tetnazepam lOmg/d; <br><br> Lithium <br><br> 900mg/d; <br><br> Benzotropine <br><br> 2mg/d <br><br> Male <br><br> 38 <br><br> 12 <br><br> years <br><br> Schizophrenia <br><br> 02/09/02 07/10/02 <br><br> 1.2 2.4 <br><br> 1.6 <br><br> 2.3 <br><br> 02/09/02 (200mcg) <br><br> Clozapine 700mg/d; Epilim 2g/d <br><br> Nine patients were studied. Prior to treatment all patients had red cell and plasma selenium levels in the 5 lower part of the range for psychiatric patients. Eight of the patients were given 200/zg of selenium per day in the form of selenium yeast and one was given 100/ig per day. At the end of the supplementation period, all the eight patients who were given 200/zg per day showed 10 plasma and red cell selenium levels in the upper part of the range for normal individuals. However, the patient given 100 /ig per day showed no change in plasma selenium and only a small rise in red cell selenium. This indicates that for many patients 100/zg per day is 15 unlikely to be sufficient whereas 2 00/tg per day is likely to be sufficient giving rise to a preferred range of daily doses from 150/xg to 300/ig per day. <br><br> The selenium may be provided in any form which may be 20 assimilated by the body. Many selenium supplements are prepared by growing yeast or possibly other microorganisms on selenium-containing medium and such yeast or other micro-organism derived sources would be appropriate. Selenium may also be chelated or 25 otherwise linked to a range of other conpounds, and in <br><br> WO 03/066071 <br><br> 9 <br><br> PCT/CB03/00490 <br><br> particular amino acids. Selenomethionine and selenocysteine are common naturally occurring compounds which are widely used as selenium supplements. Inorganic salts of selenite and also selenate may be 5 used. Any assimilable form of selenium may be employed. <br><br> The selenium may be incorporated into the actual drug delivery system whether that be tablets, liquids or 10 emulsions, hard or soft gelatin capsules, powders, drinks, foods or any other appropriate system which may be used by those skilled in the art to deliver either a drug or a selenium product. Usually the selenium will actually be incorporated into the drug formulation or 15 may be chemically linked to the drug to form a selenium-drug derivative. Sometimes it may be appropriate to provide the selenium in a separate formulation but linked to the drug in a combination package. <br><br> 20 <br><br> Example Formulations <br><br> 1. A tablet formulation of any drug for a neurological or psychiaric disorder formulated together <br><br> 25 with a selenium compound which delivers a daily amount of selenium between 10 fig and 2000 fig. The selenium may be in any biologically assimilable form including yeast selenium, selenomethionine, selenocysteine, sodium selenite or sodium selenate. <br><br> 30 <br><br> 2. As in example 1 where the formulation is a hard or soft gelatin capsule <br><br> 3. As in example 1 where the formulation is a liquid 35 or an emulsion with or without flavouring. <br><br> WO 03/066071 PCT/GB03/00490 <br><br> 10 <br><br> 4. As in example 1 where the formulation is in any-other form appropriate for oral administration including a powder or a liquid. <br><br> 5 <br><br> 5. As in examples 1-4 where the drug is clozapine or one of its derivatives. <br><br> 10 6. As in examples 1-4 where the drug is any drug for the treatment of schizophrenia including but not limited to chlorpromazine, haloperidol, risperidone, olanzapine, quetiapine, zotepine, amisulpiride, ziprasidone, sertindole, ethyl eicosapentaenoate or 15 aripiprazole. <br><br> 7. As in examples 1-4 where the drug is any drug for the treatment of depression including but not limited to amitriptyline, lofepramine, dothiepin, doxepin, <br><br> 20 trimipramine, imipramine, clomipramine, protr iptyline, nortriptyline, venlafaxine, fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram, reboxetine, mirtazepine, nefazodone, trazodone, moclobemide, viloxazine, maprotiline, phenelzine, 25 tranylcypromine or ethyl-eicosapentaenoate. <br><br> 8. As in examples 1-4 where the drug is any drug for the treatment of bipolar disorder, including but not limited to lithium salts, valproic acid and its <br><br> 30 derivatives and carbamazepine. <br><br> 9. As in examples 1-4 where the drug is any drug for the treatment of anxiety including but not limited to any benzodiazepines, any beta-blockers and buspirone. <br><br> 35 <br><br></p> </div>

Claims (6)

<div class="application article clearfix printTableText" id="claims"> <p lang="en"> WO 03/066071 PCT/GB03/00490<br><br> 11<br><br> 10. As in examples 1-4 where the drug is any drug for the treatment of epilepsy including but not limited to carbamazepine, lamotrigine, sodium valproate, phenytoin, benzodiazepines, barbiturates, topiramate,<br><br> 5 gabapentin or vigabatrin.<br><br> 11. As in examples 1-4 where the drug is any drug for the treatment of Parkinson's disease including but not limited to levodopa, benserazide, carbidopa,<br><br> 10 selegiline, tolcapone, bromocriptine, ropinirole, apomorphine, pergolide, other dopamine receptor agonists, amantadine or anticholinergic drugs.<br><br> 12. As in examples 1-4 where the drug is any drug for 15 the treatment of Huntington's disease, Friedreich's ataxia, myotonic dystrophy, amyotrophic lateral sclerosis, multiple sclerosis or any other neurodegenerative disease including but not limited to ethyl-eicosapentaenoate, riluzole, lofepramine and 20 cyclo-oxygenase 2 inhibitors.<br><br> 13. As in examples 1-4 where the drug is any drug for the treatment of any form of dementia including but not limited to donepezil, rivastigmine, or gaiantamine or<br><br> 25 any cholergic drug.<br><br> 12<br><br> WHAT WE CLAIM IS:<br><br>
1. Use of clozapine together with any biologically assimilable form of selenium in the manufacture of a medicament for the treatment or prevention of schizophrenia.<br><br>
2. Use of clozapine together with any biologically assimilable form of selenium in the manufacture of a medicament for the treatment or prevention of schizophrenia, wherein the medicament provides a daily dose of selenium between 10|jg and 2000|jg per day.<br><br>
3. The use according to claim 1, wherein the daily dose of selenium is between 50(jg and 500|jg per day.<br><br>
4. The use according to claim 1, wherein the daily dose of selenium is between 150|jg and 300|jg per day.<br><br>
5. The use according to claim 1, wherein the selenium is in the form of selenium yeast.<br><br>
6. A use of clozapine together with any biologically assimilable form of selenium in the manufacture of a medicament for the treatment of schizophrenia substantially as herein described and with reference to any one of the accompanying examples 1 to 13.<br><br> LAXDALE LIMITED By their Attorneys<br><br> JAMES &amp; WELLS<br><br> lnic-~<br><br> o.iy<br><br> </p> </div>
NZ534304A 2002-02-07 2003-02-04 Formulations comprising psychotropic drugs and selenium NZ534304A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202900.7A GB0202900D0 (en) 2002-02-07 2002-02-07 Novel formulations of drugs
PCT/GB2003/000490 WO2003066071A1 (en) 2002-02-07 2003-02-04 Formulations comprising psychotropic drugs and selenium

Publications (1)

Publication Number Publication Date
NZ534304A true NZ534304A (en) 2006-07-28

Family

ID=9930626

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ534304A NZ534304A (en) 2002-02-07 2003-02-04 Formulations comprising psychotropic drugs and selenium

Country Status (8)

Country Link
US (1) US6919330B2 (en)
EP (1) EP1478374A1 (en)
JP (1) JP2005525329A (en)
AU (1) AU2003244454A1 (en)
GB (1) GB0202900D0 (en)
NZ (1) NZ534304A (en)
TW (1) TW200404558A (en)
WO (1) WO2003066071A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010450A (en) * 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist.
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US7071879B2 (en) 2004-06-01 2006-07-04 Ems Technologies Canada, Ltd. Dielectric-resonator array antenna system
FR2873376B1 (en) * 2004-07-23 2006-11-24 Tetrahedron Sas NOVEL SELENO-HYDROXYACIDS AND DERIVATIVES, NUTRITION APPLICATIONS, COSMETICS AND PHARMACY
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2006036686A2 (en) * 2004-09-24 2006-04-06 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
ES2392443T3 (en) 2004-10-05 2012-12-10 Inovex Co., Ltd. Use of an aqueous solution containing platinum colloid for the treatment of psychiatric symptoms
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
JP4753683B2 (en) * 2005-10-14 2011-08-24 オルテック インコーポレイテッド Methods and compositions for altering cell function
WO2007109851A1 (en) * 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
CA2650309C (en) * 2006-04-24 2014-08-19 Alltech, Inc. Selenium-containing compositions and use of the same
WO2008119109A1 (en) 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090414A (en) * 1970-05-20 2000-07-18 Life Science Labs, Inc. Method and composition to reduce cancer incidence
SE7812170L (en) * 1977-12-07 1979-06-08 Klippan Nv BELT LOCK WITH EASY RELEASE LOCK
AT397200B (en) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr USE OF SELENIUM METHIONINE IN THE PRODUCTION OF A MEDICINAL PRODUCT
IL110139A0 (en) 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
US5358720A (en) 1993-10-22 1994-10-25 Koppel Richard M Treatment of arthritic conditions
HUT72422A (en) 1994-04-20 1996-04-29 Beres Export Import Rt Aquous concentrate and process for its preparation
FR2737205B1 (en) * 1995-07-26 1997-09-12 Oreal NOVEL DERIVATIVES OF N, N'-DI (ARALKYL) N, N'-DI (2-AZAARALKYL) ALKYLENE DIAMINE AND THEIR USE IN PHARMACEUTICAL AND COSMETIC COMPOSITIONS
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
AU7222598A (en) * 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
US6399114B2 (en) 2000-05-26 2002-06-04 C & D Foreman, Inc. Nutritional system for nervous system disorders
DK1163904T3 (en) 2000-06-16 2006-08-14 Matthias Dr Med Rath Composition for the prevention of smooth muscle disease comprising ascorbate, arginine and magnesium

Also Published As

Publication number Publication date
WO2003066071A1 (en) 2003-08-14
US6919330B2 (en) 2005-07-19
US20030175361A1 (en) 2003-09-18
TW200404558A (en) 2004-04-01
JP2005525329A (en) 2005-08-25
AU2003244454A1 (en) 2003-09-02
GB0202900D0 (en) 2002-03-27
WO2003066071A8 (en) 2006-08-17
EP1478374A1 (en) 2004-11-24

Similar Documents

Publication Publication Date Title
US6919330B2 (en) Formulations of drugs
Yanagisawa Zinc deficiency and clinical practice
CN101212961A (en) HMB compositions and uses thereof
US20150056297A1 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
ES2546055T3 (en) Nutritional supplements for individuals 50 years or older to improve vitality, immunity, eye and bone health
US20040005311A1 (en) Dietary supplement compositions
WO2002007768A1 (en) Dietary supplement compositions
RU2665635C2 (en) Multivitamin/mineral composition for controlling environmental stress effects; improving immunity and increasing activity, aiming at vitamin and mineral insufficiency with no negative side effects of mega-dosage food additive
US6369041B2 (en) Oral combinations of hydroxocobalamin and folic acid
JPS62277325A (en) Antidote for acetaldehyde
WO2013067485A1 (en) Nutritional supplement for weight management
AU2022264289A1 (en) Blood carnitine-increasing agent
Bhusal et al. Riboflavin deficiency
JPH04342528A (en) Agent for promotion of alcohol metabolism and acetaldehyde metabolism
Agins ADA Quick guide to drug-supplement interactions
ES2375391B1 (en) COMPOSITION OF NUTRITIONAL COMPLEMENT.
JP2004161619A (en) Osteogenic promoting composition
WO2020080398A1 (en) Agent for suppressing alcohol sickness or hangover caused by alcoholic beverage intake
Yaşar et al. Valproic acid-induced neutropenia and thrombocytopenia in a patient with schizoaffective disorder: a case report
DK201200198Y4 (en) Compositions containing cetilistate
US20210322353A1 (en) Nutritional composition for the treatment of metabolic diseases
Iqbal et al. Amin-ul aziz and Kashish Aziz (2016) Enteric Coated Iron Folic Acid Tablets: Compromised Efficacy at Cost of Safety
Walker et al. Iron supplementation and cognitive function
BE1025418A1 (en) Nutritional supplement and applications
Smith Medical Marijuana for Migraines

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed